Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Differentiated Thyroid Cancer × anlotinib × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Pheochromocytoma 2 Paraganglioma 2 Neuroendocrine Tumors 1 Digestive System Neoplasms 1 Differentiated Thyroid Cancer 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Thyrotropin Alfa 3 donafenib 2 Injections 2 surufatinib 1 pembrolizumab 1 lenvatinib 1 apatinib 1 anlotinib 1 Sorafenib 1 Iodine-131 1 Everolimus 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡